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Abstract
Mutations of the sequence-specific master regulator p53 that alter transactivation function from
promoter response elements (REs) could result in changes in the strength of gene activation or spectra
of genes regulated. Such mutations in this tumor suppressor might lead to dramatic phenotypic
changes and diversification of cell responses to stress. We have determined “functional fingerprints”
of sporadic breast cancer-related p53 mutants many of which are also associated with familial cancer
proneness such as the Li-Fraumeni Syndrome and germline BRCA1/2 mutant-associated cancers.
The ability of p53, wild type and mutants, to transactivate from 11 human target REs has been
assessed at variable expression levels using a cellular, isogenomic yeast model system that allows
for the rapid analysis of p53 function using a qualitative and a quantitative reporter. Among 50
missense mutants, 29 were classified as loss-of-function. The remaining 21 retained transactivation
towards at least one RE. At high levels of galactose induced p53 expression, 12/21 mutants that retain
transactivation appeared similar to WT. When the level of galactose was reduced, transactivation
defects could be revealed suggesting that some breast cancer related mutants can have subtle changes
in transcription. These findings have been compared with clinical data from an ongoing neoadjuvant
chemotherapy treatment trial for locally advanced breast tumors. The functional and nonfunctional
missense mutations may distinguish tumors in terms of demographics, appearance and relapse,
implying that heterogeneity in the functionality of specific p53 mutations could impact clinical
behavior and outcome.
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Introduction
The tumor suppressor p53 is a master regulatory gene that regulates the differential expression
of target genes in a sequence-specific manner in response to cellular and environmental insults
(1-3). Cell cycle regulation, apoptosis, angiogenesis, replication and repair are processes
interconnected within the p53 transcriptional network. p53 exerts itself as a transcription factor
by binding as a homotetramer, or dimer of dimers, to a consensus response element (RE)
sequence comprised of two decamer half-sites [RRRCWWGYYY]2 (where R= purine; W= A/
T; Y=pyrimidine) which vary between target genes. While the canonical consensus sequence
allows for spacing between the half-sites of up to 13 nucleotides, we recently showed that
transactivation was greatly reduced as the separation between decamers is increased beyond 2
nucleotides (4). Activation of a p53 target gene is dependent on a matrix of factors including
cell type, stimuli, post-translational modifications and transcriptional co-factors (5).
The importance of p53 as a tumor suppressor and sequence-specific transcription factor in
human cells is highlighted by the occurrence of p53 mutations in the majority of cancers (6).
Interestingly, p53 is unique in comparison to other transcription factors in that over 75% of
mutations that occur in this tumor suppressor are single amino acid changes which result in
missense mutations (7). These missense mutations predominantly occur in the DNA binding
domain (DBD) of the protein (>80%) (7). At the molecular level, p53 mutations found in
cancers, including breast cancer, are usually associated with loss of the ability to maintain
proper cell cycle checkpoints, suppress transformation caused by oncogenes, induce apoptosis
and maintain the integrity of the genome (1,8).
Specific mutations in p53 are known to denature the native protein or abrogate its ability to
bind DNA thus completely abolishing its function. Such mutations are thought to provide a
selective advantage within cancerous cells by forming a hetero-tetramer with WT p53 and
functioning in a dominant-negative fashion (9,10). Alternatively, gain-of-function mutations
can potentiate tumorigenesis through oncogenic mechanisms including aberrant transcriptional
regulation of either known or novel target genes--presumably through structure-selective DNA
binding or protein-protein interactions (9-11). Many p53 missense mutations have been
described that retain function as sequence-specific transcription factors such that the ability to
regulate cellular responses is altered, but not completely lost (2,12).
Functional mutations that alter the transcriptional capacity of the p53 master gene have been
identified as super-transactivating, change-in-spectrum or overall downward modulation of
transactivation. For example, change-in-spectrum mutants may be capable of regulating genes
containing a strong RE, such as p21, but unable to regulate those with a weak RE, such as Bax.
This is consistent with the observation of mutant p53s that still induce cell cycle arrest, yet lose
the ability to activate apoptosis (13-15). In addition, p53 mutations may alter the active binding
sites of potential transcriptional cofactors, thus diminishing the potential maximal level of
transcriptional response. Modifications in the transcriptional network due to altered-function
mutations may result in cellular responses that impact genome stability, repair, replication, and
programmed cell death. Varying patterns of cellular responses, including apoptosis and
survival have been elicited in human cells as a consequence of distinct altered-function p53
mutations (16). Furthermore, the aberrant biological consequences of specific altered-function
mutations can be influenced by specific cell type and activating stimuli.
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Mutations in p53 are associated with approximately 25% of sporadic cases of breast cancer, a
frequency lower than that in other sporadic cancers, such as lung and colorectal carcinomas.
However, sporadic p53 mutations occur at much higher frequencies in BRCA1/2 germline-
associated breast cancers possibly due to a decreased efficiency to repair damage (17,18).
BRCA1/2 and p53 are involved in maintaining genome stability by controlling aspects of
homologous recombination and repair, centrosome regulation, cell cycle checkpoints and
transcription (19), where loss of either increases the likelihood of cancer (20). Interestingly,
BRCA1-associated cancers have an altered spectrum of p53 mutations which may reflect
changes in mutagenesis and/or selection for the acquired mutations (17). While BRCA1
mutations are largely absent in somatic breast tumors, silencing of the gene through
hypermethylation has been reported in sporadic cases (21). Such epigenetic changes have been
reported to associate with estrogen receptor negative (ER-) tumors and occur concomitantly
with p53 mutations (21).
At the clinical level, p53 mutations in breast cancer have been associated with poor prognosis,
earlier on-set, increased aggressiveness of tumors, aneuploidy, and adverse responses to
chemotherapeutic treatments (22). Studies that classify breast cancers based on gene expression
profiling have shown p53 mutations are more frequent in the hormone receptor-negative
subtypes such as the HER2+/ER− [human epidermal growth factor-2 positive/estrogen
receptor negative] and the basal-like subtypes [ER−, PR− (progesterone receptor), HER2−,
cytokeratin 5/6+, and/or HER1+] (23-25). Based on a recent population-based study, these
subtypes were prevalent among African American and/or premenopausal women and
correlated with a more aggressive disease and shortened survival, irrespective of lymph node
status (25). Regardless of subtype, p53 status (WT or mutant) also displays a signature
expression profile in breast tumors which is a prognostic indicator of patient survival, where
WT p53 associates with a more favorable outcome (23,26,27).
We have employed a newly developed model system in diploid yeast (4) to analyze the
functional consequences of p53 missense mutations found in breast cancers on gene activation
endpoints in the p53 transcriptional network at various levels of p53 expression.
Transactivation capacities of WT and mutant p53 have been determined using a qualitative
and a quantitative reporter, and a “functional fingerprint” was established for each p53 variant
towards a subset of human REs that are representative of p53-dependent cellular responses.
We have determined that p53 missense mutations found in sporadic and familial breast cancers
can retain function and the alterations in transactivation are often subtle where differences can
be exaggerated by changes in p53 levels. While patient numbers are limited, the separation of
missense p53-associated breast cancer mutations into functional (which include fully
functional and altered function) versus nonfunctional classes appears to associate with
prognostic factors and outcome in a largely locally-advanced patient population treated with
chemotherapy prior to surgery. Functional fingerprinting of cancer-associated p53 mutants
may thus be a useful tool for understanding tumor biology and behavior.
Materials and Methods
Isogenomic diploid yeast strains
Two panels of isogenic haploid yeast strains, a “p53-host” and “response element (RE)
reporter” strains, were developed in the budding yeast, S. cerevisiae with the delitto perfetto
site-directed mutagenesis system as previously described (Figure 1) (4,79). Each “p53-host”
strain, yAT-iGAL::p53 (MATa leu2-3,112 trpl-1 his3-11,15 can 1-100 ura3-1,
trp5::pGAL1:p53:cyc1-Ter, lys2::HygroR), contains the wild type or mutant p53 cDNA
controlled by the inducible, “rheostatable” GAL1 promoter (2) integrated at the TRP5 locus on
chromosome VII. p53 mutations were constructed using a derivative of the previously
described p53 host strain containing a CORE cassette (CO, counterselectable, KLURA3; RE,
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reporter, KanMX4 resistance gene) integrated at various nucleotide positions spanning the p53
cDNA (4). Modifications of the p53 cDNA were performed using the delitto perfetto approach
so that CORE cassettes were replaced with an oligonucleotide containing the mutation of
interest to generate a full-length mutant p53 cDNA. (Oligonucleotide sequences are available
upon request.) Replacement of the CORE was confirmed by selection on 5-FOA and
kanamycin sensitivity. Specific p53 alterations were confirmed by colony PCR and sequencing
(Big dye, Applied Biosystems, Foster City, CA). The second panel of isogenic strains,
constructed previously, contain human target p53 REs upstream of the CYC1 minimal promoter
and either the ADE2 or firefly luciferase reporter (2,4). The RE reporter strains are also isogenic
with the p53 host strains, but LYS2 and Hygros. Mating of the reporter and p53-host strains
followed by selection for diploid cells on Lys− Hygro+ plates, results in isogenomic yeast that
enable the assessment of the transactivation potential for WT or mutant p53 proteins towards
individual REs in the p53 transcriptional network.
Qualitative ADE2 color assay
Single colony isolates of the p53-inducible RE-ADE2 reporter strains were streaked onto an
YPDA control plate containing glucose and high levels of adenine and grown to equivalent
amounts at 30°C. The plates were then replica plated onto a series of 9 plates containing
selective media with low levels of adenine [5 mg/L], 2% raffinose and increasing galactose (0,
0.001, 0.002, 0.004, 0.008, 0.016, 0.032, 0.064 and 0.128%). Transactivation capacities for the
p53 mutants were determined after three days of growth at 30°C by the ability of the mutant
to produce a change in colony pigmentation. Transactivation of the ADE2 gene, which is a
direct readout of p53 interaction with the specific RE, results in white colonies where decreased
or loss-of-transactivation of the ADE2 results in pink and red colonies, respectively (32).
Transactivation capacities for the p53 WT and mutants were determined after three days of
growth at 30°C by the ability of the mutant to produce a change in colony pigmentation. Colony
pigmentation was manually scored on a scale of 1 to 5, where 1 is no apparent transactivation
(red colonies) and 5 is strong transactivation (white colonies) (Supplemental figure 2).
Quantitative luciferase assay
Diploid yeast strains containing GAL1::p53 (WT or mutant) crossed with a specified RE-
luciferase reporter were grown overnight in 5ml YPDA plus adenine [200 mg/L] rich media.
Overnight cultures were diluted 1:50 in H2O. For each measurement, 1 ml of the diluted culture
was spun down, washed of residual glucose with H2O and re-suspended in 2mL synthetic
complete -LYS media plus 2% raffinose supplemented with increasing amounts of galactose
(0, 0.002, 0.004, 0.008, 0.010, 0.012, 0.016, 0.020, 0.024, 0.028 or 0.032%). These cultures
were grown overnight (~ 18 hr) at 30°C to ~2 − 4 × 107 per ml (late log early stationary). The
2 ml cultures were spun down and the supernatant was aspirated. The remaining pellet was
resuspended in 100 μl reporter lysis buffer (Promega, Madison, WI) and an equivalent amount
of 425-600 micron acid-washed, glass beads was added (Sigma, St. Louis, MO). Samples were
homogenized for 30 seconds in the Biospec Products, Inc. mini-bead beater (Bartlesville, OK),
briefly incubated on ice and spun for 20 minutes at 16k relative centrifugal force (rcf) in an
Eppendorf 5415R centrifuge (Batavia, IL) to separate the soluble protein fraction. The standard
protocol recommended by the manufacturer (Promega; Madison, WI) was performed for the
luciferase assay system starting with 10 μl of protein extract. Luciferase activity was measured
from 96-well, white optiplates (Perkin Elmer, Waltham, MA) in a Wallac Victor2 multilabel
counter (Perkin Elmer, Waltham, MA). Light units were standardized per μg protein as
determined by a Bio-Rad protein assay (Bio-Rad; Hercules, CA).
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Diploid yeast strains containing GAL1::p53 (WT or mutant) crossed with the p21-5′ RE-
luciferase reporter were grown as described above. Overnight cultures containing 0.024%
galactose were harvested, lysed in 35 μl reporter lysis buffer (Promega, Madison, WI) plus 2%
protease inhibitors (cocktail for use with fungal and yeast extracts; Sigma, St. Louis, MO) and
processed in the same fashion as those used in the luciferase assay. Protein concentrations were
measured with the Bio-Rad protein assay according to the standard protocol (Bio-Rad;
Hercules, CA). 50 μg of total protein was run on 4-12% BisTris NuPAGE and transferred as
previously described (32). The p53 protein was detected with a mix of DO7 (BD BioSciences
Pharmenigen) and pAb1801 (Santa Cruz) antibodies unless otherwise specified according to
the manufacturer’s protocol. Bands were detected using horseradish peroxide-conjugated
secondary antibodies (Santa Cruz) and the enhanced chemiluminescence (ECL) detection
system (Amersham, Cleveland, OH, USA). Membranes were stained with Ponceau S to
determine efficiency of protein loading.
Mutation analysis from patients participating in a neoadjuvant trial
p53 mutational analysis was performed on untreated breast cancer tissues obtained from
women participating in two clinical-translational trials, a single institution study from the
University of North Carolina–Lineberger Comprehensive Cancer Center (UNC-LCCC 9819),
and a multiinstitutional cooperative group trial sponsored by the National Cancer Institute
(CALGB 150007). In these correlative studies, women with locally advanced breast cancer
were treated first with an anthracycline generally followed by taxane-based chemotherapy
(with or without trastuzumab, depending on Her2 status). Both trials involved acquisition of
breast cancer core biopsy tissue before treatment with any chemotherapy and were designed
to examine molecular markers predicting response to cytotoxic chemotherapy (29). These
studies were approved by the institutional review boards of the University of North Carolina
at Chapel Hill and participating institutions through the Cancer and Leukemia Group B
(CALGB). All study subjects gave written informed consent to participate in the clinical trial
and the correlative science studies. p53 gene mutations were assessed using a two-tiered
screening strategy. A pre-release version of the p53 AmpliChip array (Roche Molecular
Systems) was first used to detect point mutations and 1 base pair deletions. Samples identified
as potentially positive by the AmpliChip was sequenced to confirm the mutation. Specimens
that were mutation-negative by AmpliChip were evaluated by single strand conformational
polymorphism (SSCP) analysis in p53 exons 2-11 to detect deletions larger than 1 base pair
and insertions (80). Mutations identified as potentially positive by SSCP were sequenced to
identify the mutation. To rule out the possibility that mutations occurred due to PCR errors,
we re-amplified and re-sequenced all mutation-positive specimens.
Results
Functional fingerprinting of p53 missense mutations associated with breast cancers
Budding yeast lack endogenous p53 and have been used as an in vivo test tube to analyze
directly interactions between p53 and REs in a cellular environment (2,3). Recently, we
developed a diploid yeast model system to address the contribution of RE sequence,
organization and level of human p53, as well as the consequences of mutations upon p53-
mediated transactivation (Figure 1) (4).
We sought to define how specific p53 missense mutations found in breast cancers interfere
with p53 function by assessing the ability of mutant p53 to transactivate from a panel of REs
associated with p53-dependent downstream target genes (Table 1). Fifty missense mutations
were chosen for examination if they were identified in cases of sporadic breast cancers.
Importantly, 20 were identified in patients undergoing neoadjuvant treatment for locally
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advanced breast tumors and participating in clinical trials examining biomarkers predicting
response to sequential anthracycline- and taxane-based chemotherapy prior to surgery (28,
29). Furthermore, 18 also associate with familial BRCA1/2 cancers and/or are found as
germline mutations in Li-Fraumeni Syndrome (LFS), Li-Fraumeni-like Syndrome (LFL), and/
or familial history (FH) cancer patients (Table 1). Of particular interest were mutations present
in the L2 loop, L3 loop or zinc binding regions of the protein which have been correlated with
breast cancers that are often nonresponsive to chemotherapeutic treatments including
doxorubicin, tamoxifen, and/or combined therapies of 5-flurouracil and mitomycin (19,30,
31).
The yeast ADE2 plate color assay (32) was used to determine functional fingerprints for WT
and p53 missense mutations based on their ability to transactivate from 11 different human
REs at variable levels of protein expression (Figure 2 and Supplemental Figures 1 and 2).
Briefly, single colony isolates of yeast strains containing the mutation and RE of interest were
replicated onto plates containing increasing concentrations of galactose where the ability of
the p53 variant to drive transactivation from a specific sequence could be assessed based on
colony pigmentation (see Materials and Methods and Supplemental Figure 2). The REs
analyzed are associated with known human p53 target genes involved in cell cycle, DNA repair,
apoptosis, angiogenesis, and p53 regulation (Supplementary Table 1). Mutations were
categorized as fully functional if they were indistinguishable from WT p53 in transactivation
capacity or altered function if the allele retained the ability to function from at least one RE(s),
but deviated from WT p53 in transactivation capacity from the REs examined at any of the
levels of p53 expression examined.
Among the 50 missense mutations, 29 were classified as loss-of-function due to their inability
to transactivate from any RE (Table 1). The remaining 21 (42%) mutations were able to
function from at least one RE, where the transcriptional capacities varied from different levels
of functionality to fully functional. Among the 21 functional mutations, 9 were clearly altered
in transactivation capacity at high levels of galactose (0.128% galactose) (Supplemental Figure
1) and displayed a change-in-spectrum for REs transactivated, as exemplified by reduced or
complete lack of transactivation from the 14-3-3σ and PCNA REs by P151A and R283P,
respectively, in Figure 2. Of these 9 mutations, 3 (Y220C, M237I and P278A) retained the
ability to transactivate from only the strongest REs, p21-5′ and P53R2 when p53 expression
was induced with high levels of galactose (and, in the case of P278A, MDM2 which contains
two full-site REs) (Supplemental Figure 1).
At high levels of galactose, the remaining 12 of the 21 mutants (L130V, A138V, C141W,
P151H, R174K, R174W, P190L, H214R, R267Q, V272L, E285K, and R337H) looked similar
to WT in their transactivation capacity (i.e., L130V in Figure 2, Supplemental Figure 1).
Transactivation from three biological replicates was either indistinguishable from WT p53 or
nearly identical with the exception of 1 or 2 REs at 0.128% galactose. However, when the
levels of galactose were reduced, subtle transactivation defects were revealed that further
differentiated 6 of the 12 mutants (underlined) from WT p53 at 3 or more REs. Similar to
previous studies (2), the deviation from WT p53 at lower levels of induction consisted of both
reduced and enhanced transactivation capacities from specific REs, such as the ability of
L130V to transactivate from the Cyclin G and AIP1 REs at 0.008% galactose, respectively
(Figure 2). The remaining 6 mutants remained similar to WT p53 in transactivation capacity
even at low levels of galactose with the exception of subtle variation at 1 or 2 REs. For example,
A138V was only observed to be slightly reduced in transactivation compared to WT p53
towards PCNA at 0.008% galactose (Supplemental Figure 1).
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Luciferase assays confirm transcriptional anomalies
The functional status of the 21 missense mutants that retained function and several loss-of-
function mutants was examined with a luciferase reporter assay that provides the opportunity
to quantitate transactivation from REs in late log phase growing cells. The transactivation
capacities from the p21-5′, GADD45 and 14-3-3σ REs were comparable to those with the color
plate assay in terms of classifying functional status; however, the assay provides greater
discrimination between mutant and WT p53 transactivation. Assessment of the altered-function
mutants with the luciferase assay showed varying degrees of functionality from the p21-5′ RE,
where the maximal level of transactivation was dependent on the specific mutation (Figure 3).
Similar to the results with the plate assay, several mutants (i.e., R267Q) differed from WT p53
in their ability to transactivate from the p21-5′ RE only at low levels of galactose (low p53
expression), whereas other mutations (i.e., L194P) displayed a decreased ability to transactivate
from the p21-5′ RE at all levels of induction and corresponding p53 expression. Of the 6 fully
functional mutations examined that were similar to WT p53 in terms of transactivation from
the strong p21-5′ RE in both the plate and luciferase assays, one (H214R) showed an altered
transactivation potential when assessed for transactivation from the weaker GADD45 RE in
the luciferase assay (Figure 4). H214R had an increased ability to transactivate from the
GADD45 RE in comparison to WT p53, whereas the remaining fully functional mutations,
including A138V and R174W remained indistinguishable from WT p53. Change-in-spectrum
mutations which retained transactivation function from some REs, but were devoid of function
from others, were also verified with the luciferase assays. As shown in Figure 5, Y220C was
able to transactivate from the strong p21-5′ RE, but to reduced levels; the maximal level of
transactivation was comparable to that for WT p53 transactivating from the weaker 14-3-3σ
RE. The Y220C mutant was actually unable to transactivate from the 14-3-3σ RE.
The transactivation profiles with increasing levels of galactose (i.e., increased p53 expression)
were similar between the DBD mutants and WT p53 where initial induction occurred between
0.004 – 0.008% galactose and maximal levels of transactivation were between 0.016% -
0.024% galactose (Figures 3-5). This was not observed for the tetramerization domain mutant
R337H (Figure 6). Although maximal levels of transactivation appeared similar to WT p53,
the R337H mutation clearly altered transactivation from the p21-5′, 14-3-3σ and GADD45
REs, requiring higher levels of p53 expression than WT to initiate transactivation (Figure 6).
The requirement for increased p53 levels necessary for initial transactivation by the tetrameric
mutants appeared dependent on the strength of the RE. The R337C mutation resulted in overall
reduction in transactivation.
Altered-function mutants can maintain protein levels comparable to WT p53
Protein levels were analyzed at 0.024% galactose (within the range of expression where
transactivation was shown to plateau in the luciferase assays) by Western analysis for the 21
mutations that retained function and a representative loss-of-function mutant (Supplemental
Figure 3). Of the functional mutants, 13 displayed similar levels of protein to WT p53, as did
the loss-of-function missense mutation. However, seven mutants (C141W, L194P, Y220C,
M237I, P278A, E285K and R337C) had reduced expression compared to WT p53.
Surprisingly, several of these mutants were shown to efficiently function from multiple REs
in the plate and luciferase assays. Detection of the p53 protein with additional antibodies that
recognize different epitopes was consistent with most of these mutants having reduced levels
of protein in comparison to WT p53 (Supplemental Figure 4).
Functional status and clinical response
To address how different p53 mutations might influence response to chemotherapeutics, we
examined transcriptional functional status of p53 missense mutations found in breast cancers
in relation to clinical manifestations. Twenty-nine unique p53 missense mutations analyzed
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for functionality in this study (20 mutations) or in a related haploid yeast system (14,33) have
been identified in 46 patients with locally advanced breast tumors (primarily ductal
carcinomas). The patients were participants in clinical trials that monitor clinical and
pathologic responses to neoadjuvant treatment prior to surgery (Supplemental Table 3). As
summarized in Table 2 and Supplemental Table 3, among the 46 patients, 10 of the missense
mutations (11 patients) resulted in p53s that retained function (9 altered and 1 fully functional
mutant) and 19 were loss-of-function (35 patients). This corresponded to ~24% of patients (11
among 46) having functional mutations, suggesting a significant group that might be
approached differently regarding treatments.
While the number of p53 missense mutations examined is limited, there are emerging trends
that may differentiate patients with functional (altered or fully functional) versus nonfunctional
p53 missense mutants (Table 2 and Supplemental Table 3). Among the tumors with somatic
p53 missense mutations where HER2, ER and PR status could be assessed, functional missense
mutations were more common in HER2-negative tumors (7 of 25, 28%) compared with HER2-
positive (2 of 15, 13%). Among triple negative (ER, PR, and HER2) tumors with p53 missense
mutations, 5 of 16 (31%) carried functional mutations. There appeared to be a higher frequency
of functional/total missense mutations among Caucasians and Asians (7/29 and 2/3,
respectively) than among African American patients (2/14, 14%). Functional mutations appear
to be associated with good prognostic factors such as low incidence of nodal involvement (2
of 11, 18%). Conversely, compared with functional mutations, patients carrying nonfunctional
mutations were more likely to be stage III at diagnosis (53 vs 27%), have high grade tumors
(59 vs 36%) and to relapse in distant sites (34 vs 10%), as well as local sites (12 vs 0%) although
the numbers are small. In terms of responsiveness to chemotherapy, the pathologic complete
response (pCR; i.e., eradication of tumor) was similar between patients with functional p53
mutations and nonfunctional missense mutations (21% and 27%, respectively). However,
women with nonfunctional mutations were more likely to die (36% vs 20%) at 3 years post-
treatment than those with functional mutations. While suggestive of trends, none of these
differences reached statistical significance.
Discussion
Single amino acid changes in the p53 master regulator protein that differentially impact
transactivation may result in the selective advantage of specific mutations in certain tissue
types or stages of neoplastic transformation, as well as alter the responsiveness to or the efficacy
of chemotherapeutic agents. We have used a diploid yeast system to analyze the potential
transactivation capacity for a set of p53 missense mutations associated with breast cancers.
The 50 missense mutants examined represent approximately 18% of all somatic p53 mutations
reported in the International Agency for Research on Cancer (IARC) TP53 mutation database
and 20% of all p53 missense mutations documented in breast tumors (7). Among the mutations
analyzed, one (K305M) occurs at an acetylation site in a non-structured portion of the protein,
2 (R337H and R337C) are in the tetramerization domain and the remaining 47 are distributed
across the sequence-specific DNA binding domain.
Functional fingerprinting established that 21 out of the 50 missense mutants associated with
breast cancer can retain p53 function. The effect on transactivation appears dependent upon
the specific amino acid alteration such that even different missense mutations at the same
residue can vary in the impact on p53 functionality. This is exemplified at codon 194 where
changing the leucine residue to an arginine (L194R) results in loss-of-function, whereas a
proline (L194P) results in altered function.
The majority of the altered-function mutations analyzed in this study do not seem to be the
result of a general reduction in transactivation from all REs. Rather, they appear to be change-
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in-spectrum mutants that impact the REs differentially. Since each functional p53 missense
mutation had a unique functional fingerprint (Supplemental Figure 1) ranging from severely
altered to fully functional, there may be diverse cellular effects. The functional consequences
of mutations appear not to be predictable simply by assessments of conservation, topology, or
structural models, emphasizing the need to address the function of p53 mutants in vivo
(Supplemental Table 2). For example, a recent structure-based analysis of mutations in the
DBD does not appear indicative of the in vivo transactivation capacity. Over 45% of the
predictions based on computational geometry (which assessed residual score profiles derived
from Delaunay tessellations) (7, 34) differed with results from our transactivation assays
(Supplemental Table 2).
Importantly, the differences in transactivation for all of the mutations could not be attributed
simply to protein stability since most of the p53 mutants were expressed at levels comparable
to that for WT protein. Of the mutations that had a reduced level of protein expression, the
C141W and E285K mutants were only modestly compromised for transactivation capacity in
comparison to WT p53, whereas others such as M237I and Y220C were severely compromised.
It is possible that reduced levels of protein may be due to an increased level of degradation
within the cell due to conformation changes. This could also explain associated temperature
sensitivity of some alleles, specifically Y220C, M237I, and E285K (35-37).
However, regarding these low expressing mutants, the issue arises as to whether cellular p53
protein expression is comparable between yeast and tumor cells. There are examples where
expression in yeast is matched by low or undetected levels in breast cancer cell lines (i.e.,
E285K in BT474 and MDA-MD-134VI cells (38,39) and Y220C in HCC1419 cells (40,41))
or alternatively being accumulated in the cells (i.e., M237I in SUM149PT cells (38)).
Regardless of the amount of p53 protein expressed in yeast, the results are informative for those
cases where the mutant proteins retain transactivation ability as this indicates the potential for
mutant protein to function in mammalian cells.
Breast cancer associated mutations in the DBD can modulate p53 transactivation
The DBD of p53 consists of a β-sandwich which provides a scaffold for two large β-loops, L2
and L3 that are stabilized by a zinc ion and a loop-sheet-helix motif (42,43). Mutations in the
DBD have been postulated to affect the binding affinity of p53 towards REs by abolishing
DNA contacts, decreasing the thermodynamic stability of the protein, causing local distortions
in the DNA binding surface, or enhancing the loss of the Zn ion (44,45). Mutations in the L2/
L3 loops are predicted to be highly destabilizing to the tertiary structure of p53, can cause
chemical shifts which alter the DNA binding surface and/or can alter the response to
chemotherapeutics (7,19,30,31,46).
Of the DBD mutations analyzed for transactivation potential, 16 correspond to residues in the
L3 loop and 10 are within the L2 loop; among these 26 mutants, 6 are also zinc-binding residues.
All 6 mutations (C176F, H179R, C238F, C242F, C242S, C242Y) that interfere with the
histidine or cysteine side chains involved in coordination of the Zn ion rendered the protein
nonfunctional in terms of transactivation, emphasizing the vital role of Zn in sequence-specific
DNA binding and stabilization of the p53 protein (44,47). Similarly, all the missense mutations
analyzed in the L3 loop, which binds the minor groove of DNA and partakes in the dimerization
interface between core domains (45), were loss-of-function mutations with the exception of
M237I which was very weak for transactivation. However, 4 mutants (R174K, R174W,
P190L and L194P) in the L2 loop retained function of which several (underlined) displayed
subtle alterations in transactivation capacity. These results suggest that mutations in the L2
loop, which functions as a support for the L3 loop, may be less detrimental to transactivation
potential than those of zinc binding or in the L3 loop.
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Tetramerization mutations may alter the level of p53 required for transactivation
Although the majority of p53 missense mutations occur in the DBD, several missense mutations
have been found in the tetramerization domain that are associated with germline syndromes
and are found in sporadic breast tumors. R337C is a partial function mutation associated with
LFS (48). R337H has been associated with pediatric cases of adrenocortical carcinoma (ACC);
however, it may be a low penetrant LFS or LFL allele as well (49-52). The functional
fingerprints varied between these two altered-function mutations in that R337C had a greater
impact on p53 transactivation displaying an overall dampening effect from the various REs.
This reduced transactivation may reflect a greater instability of the protein as depicted in the
protein analysis (Supplemental Figures 1-4). Contrary to previous reports, the p53 missense
mutation R337H was not a silent mutation, but displayed altered function when examined in
the ADE2 phenotypic assay (Supplemental Figure 1). At high levels of galactose induction
(i.e., high levels of p53 expression from the GAL1 promoter), R337H looked identical to WT
p53 in the color assay. At low levels of galactose, R337H had a reduced ability to transactivate
from REs in comparison to WT p53, presumably due to its reduced ability to form tetramers.
Interestingly, the luciferase assay revealed a pattern of transactivation that was unique to
R337H where higher levels of protein expression were required to detect transactivation. This
altered pattern of transactivation may be a manifestation of the novel features of R337H which
include a pH-dependent instability and formation of amyloid-like fibrils (53,54).
Subtle variation in transactivation capacity of altered-function missense mutations
Especially interesting is the observation that many of the mutants looked similar to WT p53
when examined at high levels of galactose (i.e., high p53 expression) yet were altered function
at lower levels of galactose, consistent with our earlier findings (32). Importantly, these
mutations would not have been distinguished from WT p53 in typical functional assays where
p53 is expressed at high levels from a constitutive promoter. Thus, by reducing the level of
transcription with the rheostatable promoter, it was possible to unmask subtle transcriptional
discrepancies. These mutants might have unique properties in terms of biological
consequences. Possibly, the mutants function similarly to WT p53 for gene expression from
target genes under high stress and chemotherapeutic conditions, but differently under
conditions of low p53 expression. Also, other transcription factors could further modify the
response (3).
Although mutations in p53 are often associated with nuclear accumulation of the protein, recent
evidence indicates this may not always apply in vivo. For example, Tsuda and Hirohashi (55)
showed with immunohistochemical analysis of over 50 human breast-cancer tissue specimens
that nuclear accumulation of the p53 protein was dependent on the type and position of the
mutation, where missense mutations did not always result in stabilization of the protein.
Similarly, in a study comparing immunohistochemical analysis with cDNA-based sequencing
using ~300 primary breast tumor samples (56), in over 30% of the cases where a mutation was
observed through sequencing there was not a corresponding accumulation of p53 protein.
Recent results with knock-in mouse models indicate levels of mutant p53 can be regulated in
both normal and some tumor cells (57,58). The accumulation of mutant protein does not occur
until additional mutations are acquired in genes which may disrupt the p53 degradation
pathway such as MDM2 or p16INK4a (59). Although the subtle altered-function mutations
identified in the present study retain the ability to function from the MDM2 RE, Lukashchuck
and Vousden (60) have shown that the ability of p53 to transactivate MDM2 is not essential
for degradation of the mutant p53 protein. Rather, additional E3 ubiquitin ligases, such as CHIP
(C terminus of Hsc70-interacting protein), can target mutant p53 for degradation independent
of ubiquitination by Mdm2, where Mdm2 plays a role in delivering the ubiquitinated proteins
to proteasomes.
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The functional relevance of p53 at low expression levels is beginning to be elucidated and
highlights the need to understand mutants under such conditions. Espinosa et al. (61) observed
that p53 occupies some target REs, including p21, prior to overall p53 stabilization. There is
transcriptional initiation from these REs, but the transcriptional machinery stalls prior to
elongation. Such regulation may be required for a rapid response to cellular stress. In addition,
there is a transcriptional-dependent role for p53 in promoting cell survival, as well as
modulating glucose metabolism and reactive oxygen species at basal levels of p53 expression
(62,63). For example, p53 has been found to target the sestrins (i.e., SESN1 and SENS2) and
TIGAR (TP53-induced glycolysis and apoptosis regulator) to stimulate antioxidant and pro-
survival signals (62,63). The loss of transactivation function at low levels, as observed for some
of the subtle, altered-function mutants, might lead to alternative modes of promoter selectivity,
and/or provide the opportunity for competing transcription factors to bind promiscuously to
p53 target elements. Furthermore, p53 has also been found to promote, presumably in a
transcriptional-independent fashion, global chromatin relaxation (64). This appears to
influence genomic repair in response to UV stress at exposures that are lower than those
required for its activation as a transcription factor.
It is possible that mutations that subtly affect transactivation are acquired early in tumor
development and when combined with mutations in other genes contribute in an additive
fashion to the complex cancer disease. For example, the altered-function P190L and H214R
mutants that were indistinguishable from WT at higher levels of galactose-induced expression
are associated with germline BRCA1 and BRCA2 mutations, respectively. Such mutations in
p53 may be an underlying contributor to the genomic instability observed in BRCA1-associated
breast cancer cases and the functional status of individual p53 missense mutations may impact
the degree of genetic imbalance. Interestingly, a recent hierarchical clustering analysis using
immunohistochemistry profiling to determine the relatedness of tumors has established that
the extent of genomic instability correlates with specific breast cancer subtypes, where the
basal subtype (the subtype in which p53 mutations are frequently observed) had the highest
number of genomic aberrations in both sporadic and familial BRCA-associated cases
(65-67).
In addition, inherited p53 mutations may influence tumor type and penetrance of the disease
(57,58,68,69). LFS and LFL germline disorders--which often harbor a p53 mutation--display
an array of early onset, tissue specific tumors of which breast tumors are among the most
frequent observed (7,68). Recent studies which have assessed the functional status of p53
germline mutations using yeast-based assays have related severity of inherited p53 missense
mutations in terms of transcription functionality with clinical manifestations (7,70). Partial
deficiency alleles, defined by the ability to transactivate from at least one RE to 25% of the
levels obtained by WT p53, are associated with a less severe family history, lower number of
tumors, later onset of disease in comparison to severe deficiency (loss-of-function) alleles and
a higher risk of breast tumors.
In another recent study (71), the frequency and average size (bp deletion or duplication) of
DNA copy number variation is enriched in carriers of germline TP53 mutations within LFS
families in comparison to those with WT p53 or in a healthy population. The clinical
phenotypes which arise in later generations may correlate with greater genomic instability, as
well as specific germline p53 mutation. Thus, the wide spectrum of transcription potentials of
the 12 p53 missense mutations associated with germline disorders in the current study (ranging
from nonfunctional to altered and subtle, or fully functional) can be expected to result in varying
phenotypes where the severity of the disease is likely influenced by the extent of p53
functionality.
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Functional status and clinical response
We examined transcriptional functional status of p53 missense mutations found in breast
cancers in relation to clinical manifestations (Table 2 and Supplemental Table 3). While the
number of breast cancer-associated functional p53 mutants was small, there were trends
described in the Results that suggest differences in presentation and outcome between
functional versus nonfunctional missense mutations. The nonfunctional missense mutations
are associated with clinical responses similar to those in our studies with null mutations (data
not shown) which are known to have poorer prognosis and reduced survival as compared to
patients with tumors that are WT for p53 (72). We have found that functional p53 mutations
appear to have better disease-free survival compared with loss-of-function mutations (Table
2).
In terms of clinical response to chemotherapy, we observed in the present study a higher
response rate for tumors expressing loss-of-function p53 mutations which may seem
counterintuitive. However, tumors with p53 mutations in general are more chemo-sensitive,
possibly because the breast cancer subtypes which usually have a higher proportion of p53
mutations (e.g. the basal-like) are more highly proliferative or have aberrant DNA repair
functions (23,25). Also, the cumulative response to anthracycline/cyclophosphamide followed
by taxane therapy was determined in this study. While there is some indication from the
literature that p53 mutant status could confer different responses to these single agents
(73-75), it is difficult to predict responses to the sequential treatment. While previous studies
have investigated correlations between p53 mutations and pathologic variables in breast
cancers, few studies have attempted to correlate the transcriptional activity of specific
mutations with clinical phenotypes. In a large scale study of a cohort of approximately 1,800
woman (72), the presence of a p53 mutation was associated with high grade, positive node
status, loss of hormone receptors and greater risk of death due to breast cancer within a 10 year
follow-up. However, when the functional status of the missense mutations was taken into
consideration, no correlation was found between p53 transactivation activity and patient
survival. Importantly, the functional status of the missense mutations was determined with
another yeast-based functional assay developed by Kato et al. (12) that uses a high p53
expression plasmid along with a high copy RE reporter plasmid system.
Functional analysis based on the Kato et al. system is available at the IARC p53 mutation
database for 49 of the 50 mutations examined in the present study (7). Interestingly, a
comparison between the two data sets shows less than 65% agreement in terms of overall
transactivation functionality (Supplemental Table 2). Only 8/49 or 16% of the missense
mutations were previously identified as functional as compared to 21 mutations in the present
study system. The large discrepancy between the two systems may be in part due to the method
of classifying a mutation as retaining function (Supplemental Table 2) (7,12). For example,
we concluded that the R337C was an altered-function missense mutation whereas within the
IARC database it is considered to be a nonfunctional mutation although it did display
transactivation for 3 of the 8 REs analyzed (WAF1, MDM2 and P53R2) (7). Furthermore, in
a separate analysis, the Kato et al. group (37) found that greater than 140 missense mutations
were temperature sensitive for transactivation capacity towards at least one RE; this indicated
there may be cellular conditions under which these mutations may become functional.
Interestingly, 5 of these temperature sensitive mutations which were reported as loss-of-
function in the IARC database were classified as altered-function in the present study (P151A,
H214R, V272L, R283P and E285K). Another mutation Y220C had also been categorized as
loss-of-function; however, we have diagnosed this as a weak altered-function protein and
previously it was reported as temperature sensitive in mammalian cell assays (35).
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Given the heterogeneity of breast cancers, understanding the consequences of altered-function
mutations on the p53 transcriptional network will help elucidate how specific mutations
predispose and/or contribute to the development, penetrance and phenotype of breast cancers.
Among fifty p53 mutations identified in breast cancers, 21 had altered function—not simply
complete loss—towards at least one RE. Although the transcriptional effects associated with
these mutations are often subtle, we found that by reducing the level of transcription with the
rheostatable promoter, it is possible to address the retained functions of mutant p53 and novel
features in transcriptional networks. It is important to emphasize that the yeast-based results
indicate the potential for transactivation and that many factors can come into play in p53
mediated transactivation in human cells. Because of the wide range of p53 expression, the
present study also provides greater opportunity to identify change-of-spectrum mutants, as well
as subtle changes in transactivation.
While beyond the scope of the present study, this system may also be used to address the
biological activity of the multiple p53 isoforms from specific response elements. Given that
p53 isoforms are known to be differentially expressed in breast tumors in comparison to normal
breast tissue (76), the ratios at which these isoforms are expressed, which can change with the
presence of a mutation, may alter the transactivation profiles of wild type and/or mutant p53.
For example, similar to the p53 family members p63 and p73, specific p53 isoforms can
influence promoter selection or functionality from specific response elements through either
synergistic or antagonistic mechanisms (76,77).
Results obtained with the yeast functional assay appear predictive of whether a mutation will
also have a biological impact in mammalian cells (16). While the yeast-based assay can predict
the potential for specific p53 mutations to display altered function, assays in mammalian cells
can ascertain the full impact of the functional mutations in the presence of p53 transcriptional
cofactors and in the endogenous chromatin context of the RE. However, we propose that
assessments of functional fingerprints for p53 missense mutations associated with breast cancer
in yeast provide diagnostic value and with further study may also be used as a prognostic tool
for implementing chemotherapeutic treatment. This would be particularly relevant to the
tailoring of individual therapies, especially when the treatment agents impact p53-dependent
biological responses. Furthermore, the technique of functional fingerprinting will be useful in
determining if p53 dysfunction as a transcription factor can also be corrected by agents that
reverse its structural stability, such as the carbazole derivative PhiKan083 acting on Y220C
(78).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Evaluation of transactivation potential towards REs by WT and mutant p53s at variable
levels of expression
The budding yeast S. cerevisiae is used as an in vivo test tube to assess the consequences of
p53 missense mutations associated with breast cancer on transactivation capacity from human
RE targets. Isogenomic diploid yeast strains were generated by mating haploid “p53-host”
strains with “RE-reporter” strains of opposite mating types. Each haploid strain was
constructed with the delitto perfetto in vivo mutagenesis system where p53 and the REs were
integrated into the chromosomes as previously reported (4,79). Importantly, all of the
conditions within the diploid yeast are constant except for the p53 mutation of interest or a few
nucleotide differences in the RE sequence. The rheostatable GAL1 promoter allows for tight
regulation of p53 expression where increasing levels of galactose allow for over 150- fold
induction in protein expression (4). Regulation of protein expression allows for ascertainment
of functional discrepancies between WT and mutant p53 transactivation at variable expression
levels. Since p53 is not endogenous in yeast and human p53 can utilize the yeast transcriptional
machinery, placement of the reporter downstream of the minimal CYC1 promoter provides the
opportunity to directly monitor p53 interactions with RE sequence.
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Figure 2. Functional fingerprints of p53 mutants reveal subtle transactivational differences
The ADE2 plate color assay was used to assess the transactivation capacity of WT and mutant
p53 towards 11 human target REs at various protein concentrations. Transcription of ADE2 is
dependent on the ability of p53 (WT or mutant) to interact with and transactivate from the
specific RE sequence upstream of the minimal CYC1 promoter and the reporter. The ADE2
color assay scores p53 transactivation capacity from a RE based on colony pigmentation which
ranges from red (no transactivation) to pink (weak to moderate) to white (strong) depending
on the extent of ADE2 transcription (33). The level of p53 expression was controlled by replica
plating strains onto plates containing rich media, raffinose (2%) as the carbon source, plus
various amounts of galactose (0 – 0.128%) in the presence of low levels of adenine (5mg/L).
Shown are examples of functional fingerprints for WT p53 and several change-in-spectrum
mutations at 4 levels of protein expression. At high expression levels (0.128%) several
mutations were found to display an altered spectrum of REs regulated in comparison to WT
p53, for example, P151A and R283P. However, several mutants, such as L130V, appear
indistinguishable from WT p53 in transactivation capacity. Reducing the levels of expression
with the rheostatable promoter, exaggerated the subtle transcriptional effects of these mutations
and distinguished them from WT p53 and other mutations in transactivation capacity.
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Figure 3. Assessment of WT and mutant p53 transactivation towards the p21-5′ RE using a
luciferase assay
Diploid yeast strains containing GAL1::p53 (WT or mutant) and the p21-5′ RE-luciferase
reporter strain were grown overnight in complete medium, diluted, washed and inoculated into
selective medium containing either raffinose (2%) or raffinose (2%) plus increasing
concentrations of galactose (0 – 0.024%) for an additional night at which point the cultures in
late logarithmic growth. Protein lysates were obtained and a quantitative luciferase assay was
used to determine the transactivation capacity for the p53 variants from the p21-5 RE’. The
strength of transactivation was calculated as relative light units/ug protein. Depicted are the
mean and standard error of measurement (SEM) for 7 independent experiments. The
transactivation responses to increasing galactose can be described as basal, linear-increase, and
plateau. Maximal transactivation is dependent on the p53 variant. Many p53 missense
mutations associated with breast cancers, i.e. R174W and R267Q, do not affect the maximal
level of transactivation towards the strong p21-5′ RE in comparison to WT p53. However,
transactivation can be altered at low levels of galactose which correspond to low levels of p53
expression. Several mutants, such as L194P, were shown to modulate the levels of
transactivation at all concentrations of expression. C242S is a loss-of-function mutation.
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Figure 4. Transactivation from the GADD45 RE distinguishes altered-function mutants from WT
p53
The ability of p53 (WT and mutant) to transactivate from the GADD45 RE was measured 24
hours after inoculation into increasing concentrations of inducing media with a quantitative
luciferase assay (see Figure 4.2). The strength of transactivation was calculated as relative light
units/μg protein. Transactivation from the GADD45 RE can differentiate mutant p53 alleles
that looked similar to WT p53 in the ADE2 plate assay. H214R has an increased ability to
transactivate from the GADD45 RE in comparison to WT p53 at low and high levels of
expression, whereas A138V and R174W had similar transactivation potentials. Presented are
the mean and standard error of measurement (SEM) for 6 independent experiments.
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Figure 5. Change-in-spectrum p53 missense mutations can eliminate REs from the p53
transcriptional network
To establish that change-in-spectrum mutations are capable of altering the transcriptional
network as a result of eliminating transcription from several REs, transactivation was assessed
for WT and Y220C p53 from the p21-5′ and GADD45 REs. Diploid yeast strains were grown
overnight in complete medium, diluted, washed and inoculated into induction media. Protein
lysates were obtained from overnight cultures and quantitative luciferase assays were used to
determine the transactivation capacity of the p53 variants from the p21-5′ RE. Y220C is capable
of transactivating from the p21-5′ RE to levels comparable to WT p53 transactivation from the
weaker 14-3-3σ RE. However, Y220C was not capable of transactivating from the 14-3-3σ RE
suggesting this target gene may be eliminated from the p53 transcriptional network for this
particular mutant. The strength of transactivation was calculated as relative light units/μg
protein. Depicted are the mean and standard error of measurement (SEM) of 6 independent
experiments.
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Figure 6. Altered-function mutations at the same codon in the tetramerization domain display
different transactivation capacities
Transactivation capacities were obtained for the R337C and R337H mutants towards the
p21-5′, 14-3-3σ, and GADD45 REs at increasing levels of expression with the quantitative
luciferase assay. The levels of transactivation were severely diminished with R337C. R337H
required an increased amount of p53 expression to stimulate transactivation. The magnitude
of effect for R337C and R337H was dependent on the RE examined.
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Table 2
Clinical characteristics and response to therapy in patients with p53 functional or nonfunctional missense mutants.








Median age 49 49
Race/ethnicity
Caucasian 7/11 (64%) 22/35 (63%)
African-Americans 2/11 (18%) 12/35 (34%)
Asian 2/11 (18%) 1/35 (3%)
Node-positive 2/11 (18%) 17/34 (50%)
Stage
II 7/11 (64%) 12/34 (35%)
III 3/11 (27%) 18/34 (53%)
Inflammatory 1/11 (9%) 4/34 (12%)
Overall grade
1 1/11 (9%) 0
2 3/11 (27%) 8/34 (23%)
3 4/11 (36%) 20/34 (59%)
Indeterminate 3/11 (27%) 6/34 (18%)
Immunohistochemical subtype
HER2 negative 7/9 (78%) 18/31 (58%)
Triple negative (ER, PR, HER2) 5/9 (56%) 11/23 (48%)
Pathologic complete response to therapy 3/11 (27%) 7/34 (21%)
Clinical response to chemotherapy 8/10 (80%) 29/33 (88%)
 Recurrence (at approximately 3 y follow-up)
Local 0/10 4/34 (12%)
Distant metastasis 1/10 (10%) 12/35 (34%)
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